Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 210.0
(-1.41%)
TWD 210.0
(-1.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.1 Billion TWD | 35.91% |
| 2022 | 3.02 Billion TWD | 115.25% |
| 2021 | 1.4 Billion TWD | 36.67% |
| 2020 | 1.02 Billion TWD | 54.92% |
| 2019 | 662.8 Million TWD | 566.3% |
| 2018 | 99.47 Million TWD | 1194.42% |
| 2017 | 7.68 Million TWD | 105.73% |
| 2016 | -134.04 Million TWD | -228.95% |
| 2015 | 103.94 Million TWD | 123.51% |
| 2014 | -442.12 Million TWD | -3820.98% |
| 2013 | 11.88 Million TWD | 106.15% |
| 2012 | -193.23 Million TWD | -403.17% |
| 2011 | -38.4 Million TWD | -355.15% |
| 2010 | 15.05 Million TWD | 382.87% |
| 2009 | 3.11 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.03 Billion TWD | 159.1% |
| 2024 Q2 | 1.33 Billion TWD | 28.49% |
| 2023 Q4 | 399.95 Million TWD | -67.9% |
| 2023 Q2 | 1.26 Billion TWD | 6.02% |
| 2023 Q3 | 1.24 Billion TWD | -1.57% |
| 2023 FY | 4.1 Billion TWD | 35.91% |
| 2023 Q1 | 1.19 Billion TWD | 612.34% |
| 2022 FY | 3.02 Billion TWD | 115.25% |
| 2022 Q3 | 2.07 Billion TWD | 534.59% |
| 2022 Q4 | 167.6 Million TWD | -91.94% |
| 2022 Q1 | 446.1 Million TWD | 77.28% |
| 2022 Q2 | 327.67 Million TWD | -26.55% |
| 2021 Q3 | 348.27 Million TWD | -1.78% |
| 2021 Q4 | 251.63 Million TWD | -27.75% |
| 2021 FY | 1.4 Billion TWD | 36.67% |
| 2021 Q1 | 448.88 Million TWD | 41.18% |
| 2021 Q2 | 354.57 Million TWD | -21.01% |
| 2020 Q1 | 131.5 Million TWD | -5.61% |
| 2020 Q4 | 317.95 Million TWD | 14.08% |
| 2020 Q2 | 298.61 Million TWD | 127.07% |
| 2020 Q3 | 278.71 Million TWD | -6.66% |
| 2020 FY | 1.02 Billion TWD | 54.92% |
| 2019 Q2 | 48.46 Million TWD | -82.4% |
| 2019 Q4 | 139.32 Million TWD | -30.2% |
| 2019 FY | 662.8 Million TWD | 566.3% |
| 2019 Q1 | 275.42 Million TWD | 282.04% |
| 2019 Q3 | 199.6 Million TWD | 311.88% |
| 2018 Q2 | -55.5 Million TWD | -457.92% |
| 2018 FY | 99.47 Million TWD | 1194.42% |
| 2018 Q4 | 72.09 Million TWD | 6.99% |
| 2018 Q3 | 67.38 Million TWD | 221.39% |
| 2018 Q1 | 15.5 Million TWD | 576.73% |
| 2017 Q2 | 34.87 Million TWD | 148.2% |
| 2017 FY | 7.68 Million TWD | 105.73% |
| 2017 Q4 | -3.25 Million TWD | -106.72% |
| 2017 Q1 | -72.35 Million TWD | 60.32% |
| 2017 Q3 | 48.41 Million TWD | 38.84% |
| 2016 Q1 | 63.82 Million TWD | 114.77% |
| 2016 Q4 | -182.36 Million TWD | -464.34% |
| 2016 Q3 | -32.31 Million TWD | -292.15% |
| 2016 FY | -134.04 Million TWD | -228.95% |
| 2016 Q2 | 16.81 Million TWD | -73.65% |
| 2015 FY | 103.94 Million TWD | 123.51% |
| 2015 Q3 | 15.15 Million TWD | -83.04% |
| 2015 Q4 | 29.71 Million TWD | 96.07% |
| 2015 Q2 | 89.36 Million TWD | 395.05% |
| 2015 Q1 | -30.28 Million TWD | 82.83% |
| 2014 Q1 | -50.83 Million TWD | -236.57% |
| 2014 Q4 | -176.41 Million TWD | -104.57% |
| 2014 Q3 | -86.23 Million TWD | 29.35% |
| 2014 Q2 | -122.06 Million TWD | -140.12% |
| 2014 FY | -442.12 Million TWD | -3820.98% |
| 2013 Q1 | 29.48 Million TWD | 138.42% |
| 2013 Q4 | -15.1 Million TWD | -436.47% |
| 2013 Q3 | 4.48 Million TWD | 164.26% |
| 2013 Q2 | -6.98 Million TWD | -123.7% |
| 2013 FY | 11.88 Million TWD | 106.15% |
| 2012 FY | -193.23 Million TWD | -403.17% |
| 2012 Q1 | -35.89 Million TWD | -1470.48% |
| 2012 Q2 | -83.84 Million TWD | -133.59% |
| 2012 Q3 | 1.71 Million TWD | 102.04% |
| 2012 Q4 | -76.73 Million TWD | -4576.95% |
| 2011 Q1 | -2.27 Million TWD | -112.98% |
| 2011 Q2 | 72.33 Million TWD | 3283.71% |
| 2011 Q3 | -111.08 Million TWD | -253.57% |
| 2011 Q4 | 2.61 Million TWD | 102.36% |
| 2011 FY | -38.4 Million TWD | -355.15% |
| 2010 Q3 | 1.41 Million TWD | -80.07% |
| 2010 Q2 | 7.07 Million TWD | 164.7% |
| 2010 Q1 | -10.94 Million TWD | 0.0% |
| 2010 Q4 | 17.5 Million TWD | 1140.47% |
| 2010 FY | 15.05 Million TWD | 382.87% |
| 2009 FY | 3.11 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Grape King Bio Ltd | 1.45 Billion TWD | -182.615% |
| Standard Chem & Pharm CO., LTD. | 834.88 Million TWD | -391.759% |
| Maywufa Company Ltd. | 169.09 Million TWD | -2327.957% |
| ScinoPharm Taiwan, Ltd. | 287.05 Million TWD | -1330.253% |
| LIWANLI Innovation Co., Ltd. | 5.1 Million TWD | -80355.144% |
| YungShin Global Holding Corporation | 827.3 Million TWD | -396.266% |
| PhytoHealth Corporation | -47.11 Million TWD | 8813.683% |
| SCI Pharmtech, Inc. | 294.72 Million TWD | -1293.055% |
| Formosa Laboratories, Inc. | 126.24 Million TWD | -3152.161% |
| PharmaEssentia Corporation | -623.83 Million TWD | 758.127% |
| Bora Pharmaceuticals Co., LTD. | 3.03 Billion TWD | -35.493% |